STAC

Jabil Expands Cloud-Server Capabilities with Enhanced Performance, Precision Timing and Greater Flexibility for Financial Services Industry Demands

Retrieved on: 
Mittwoch, Mai 29, 2024
Semiconductor, Automotive Manufacturing, Aerospace, Manufacturing, Nanotechnology, Other Technology, Software, Finance, Networks, Internet, Banking, Hardware, Professional Services, Data Management, Technology, Mobile, Wireless, Fintech, Other Manufacturing, Engineering, Cloud, STAC, Learning, Inc., Xeon, FSI, Jabil, JBL, Architecture, CPU, PTM, Operational technology, 2U, Video game

The enhanced servers are powered by 5th Gen Intel® Xeon dual socket processors and feature customizable, high-speed, and low-latency I/O options to address the arduous processing demands of the financial services industry (FSI) while achieving CPU and applications synchronization with nanosecond precision.

Key Points: 
  • The enhanced servers are powered by 5th Gen Intel® Xeon dual socket processors and feature customizable, high-speed, and low-latency I/O options to address the arduous processing demands of the financial services industry (FSI) while achieving CPU and applications synchronization with nanosecond precision.
  • “Jabil continues to build upon the success of our highly configurable server offerings to deliver better response times for financial service applications,” said Ed Bailey, CTO of Cloud and Enterprise Infrastructure, Jabil.
  • Moreover, Jabil is developing next-generation proof-of-concept servers designed to deliver even greater levels of accuracy with targets set on pico-second precision.
  • The Jabil FSI optimized server portfolio includes:
    J322-S: A 2U server optimized for PTM, offering scalability and I/O flexibility.

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Retrieved on: 
Donnerstag, Mai 9, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, STAC, FDA, CTA, Haemophilia, Enzyme replacement therapy, Kite, Investment, Nav1.7, Fabry disease, Poster, Disease, ERT, Sigma-Aldrich, STAAR, Health care, MAA, Partnership, Sangamo Therapeutics, MINT, AAV, Ligand Pharmaceuticals, IND, Tauopathy, Novartis, DNA, Patient, Pivotal, DSM-IV codes, EMA, Prion, BBB, Genome, BLA, MHRA, Manuscript, BioRxiv, Capsid, Modularity, Biogen, Therapy, Food and Drug Administration, European Medicines Agency, Gene, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
  • “We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program.
  • An IND submission is expected in the fourth quarter of 2024.
  • Revenues for the first quarter ended March 31, 2024 were $0.5 million, compared to $158.0 million for the same period in 2023.

Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions

Retrieved on: 
Mittwoch, Mai 8, 2024
STAC, Seer, CCO, Health, University Hospital Bonn, Proteomics, Research, Workflow, Proteome, Disease, Life, Automation, Biology, Mass spectrometry, Drug development

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced the launch of the Seer Technology Access Center (STAC) in Bonn, Germany, providing the European biopharma and life sciences communities with service programs and the latest mass spectrometry technologies to optimize deep, unbiased proteomic studies. The new facility, opening in June, will be located at Life & Brain GmbH, an independent commercial technology provider, on the campus of the University Hospital Bonn. In June 2023, Seer established the first Seer Technology Access Center at the company’s headquarters in Redwood City, California.

Key Points: 
  • The new facility, opening in June, will be located at Life & Brain GmbH, an independent commercial technology provider, on the campus of the University Hospital Bonn.
  • In June 2023, Seer established the first Seer Technology Access Center at the company’s headquarters in Redwood City, California.
  • The Seer Technology Access Center in Europe will help address an unmet need for researchers who want to conduct deep, unbiased proteomics studies to accelerate biomarker discovery and drug development.
  • To learn more about Seer’s Technology Access Center, contact your local Seer representative by requesting a consultation at www.seer.bio .

Seer Reports First Quarter 2024 Financial Results

Retrieved on: 
Mittwoch, Mai 8, 2024
STAC, Investment, Proteomics, Webcast, Share repurchase, SP100, Chair

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2024.
  • Gross profit, inclusive of grant and other revenue, was $1.4 million and gross margin was 44% for the first quarter of 2024.
  • Net loss was $20.7 million for the first quarter of 2024, as compared to $24.0 million for the corresponding prior year period.
  • Seer will host a conference call to discuss the first quarter 2024 financial results on Wednesday, May 8, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time.

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Montag, April 22, 2024
Research, Infectious Diseases, Neurology, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, STAC, Neuron, Central nervous system disease, Dravet syndrome, Central nervous system, MD, Sangamo Therapeutics, Cell, AAV, Tauopathy, CNS, Engineering, DNA, Charcot–Marie–Tooth disease, Patient, Gene, Society, DSM-IV codes, Prion, Angelman syndrome, ALS, Genome, Capsid, Therapy, Powder metallurgy

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual Meeting being held May 7-11, 2024, in-person in Baltimore, MD and in a virtual format.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual Meeting being held May 7-11, 2024, in-person in Baltimore, MD and in a virtual format.
  • Presentations will focus on the progression of Sangamo’s neurology-focused pre-clinical pipeline, including data supporting innovations in zinc finger epigenetic regulation, advances in AAV capsid engineering, and discovery of next-generation integrase technology.
  • These data will showcase a novel AAV capsid, STAC-BBB, that exhibited robust and widespread central nervous system transduction in cynomolgus macaques after intravenous delivery, as well as another novel AAV capsid, STAC-150, engineered to accelerate the discovery of potent and highly specific epigenetic regulators.
  • Sangamo will also present additional data from its AAV capsid engineering platform SIFTER and its efforts for integrase evolution and utilization.

Philadelphia Phillies and NEST launch Skilled Trades All-Star Program to Ignite Interest in Skilled Trades Among Youth

Retrieved on: 
Donnerstag, April 18, 2024
STAC, Citizens Bank Park, Construction, Tradesman, OVG, Philadelphia Phillies, Oak View Group, Tech High School, Student, NEST, HVAC, Associated Builders and Contractors

PHILADELPHIA, April 18, 2024 /PRNewswire/ -- The Philadelphia Phillies and NEST, the pioneer of integrated facilities management, are joining forces to launch the Skilled Trades All-Star Program, a dynamic initiative aimed at guiding Philadelphia-area youth towards promising careers in the skilled trades. The initiative kicks off with a series of educational events at Citizens Bank Park this season.

Key Points: 
  • PHILADELPHIA, April 18, 2024 /PRNewswire/ -- The Philadelphia Phillies and NEST, the pioneer of integrated facilities management, are joining forces to launch the Skilled Trades All-Star Program, a dynamic initiative aimed at guiding Philadelphia-area youth towards promising careers in the skilled trades.
  • "The Skilled Trades All-Star Program isn't just about a single day at the ballpark; it's about sparking a lifelong interest in the trades that build and sustain our communities.
  • The Skilled Trades All-Star Program is a direct extension of STAC's mission, seeking to illuminate the path for youth toward these essential roles.
  • "Rejuvenating the skilled trades has been a priority for us at NEST and the founding members of the Skilled Trades Advisory Council, and we are making incredible progress," said Rob Almond, CEO of NEST.

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Mittwoch, März 13, 2024
Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, STAC, Gene, Orphan drug, ALTA, Haemophilia A, BBB, Patient, Health care, Quality of life, IND, Male, ERT, Investment, Therapy, Fabry disease, Plasma, Kite, Gene expression, Partnership, Central nervous system, Novartis, CNS, Pivotal, EMA, Prion, STAAR, Enzyme replacement therapy, Biogen, Tauopathy, Workforce, BLA, AAV, Sanofi, Research, DRG, Neuron, Hematology, FDA, DSM-IV codes, Brain, Sangamo Therapeutics, MAA, Haemophilia, CTA, Mouse, Female, Traffic barrier, Sodium, MHRA, Excipient, Society, Spinal cord, Toxicology, Sigma-Aldrich, Liver, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.
  • “In 2023, Sangamo announced the prioritization of its pipeline programs that support our focus as a neurology-focused genomic medicine company,” said Sandy Macrae, Chief Executive Officer of Sangamo.
  • STAC-BBB was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues.
  • Revenues for the fourth quarter ended December 31, 2023 were $2.0 million, compared to $27.2 million for the same period in 2022.

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Retrieved on: 
Mittwoch, März 13, 2024
Research, Neurology, Genetics, Clinical Trials, Health, Pharmaceutical, General Health, Other Science, Science, STAC, AAV, Sangamo Therapeutics, Gene, Brain, Capsid, Gene expression, ALS, BBB, Central nervous system, Novartis, CNS, CTA, DRG, Traffic barrier, Prion, NHP, Tropism, IND, Nav1.7, Neuron, Biogen, Tauopathy, Excipient, Therapy, DSM-IV codes, Spinal cord, Liver, Animal, Vaccine

Sangamo is exploring avenues to resume development of these programs internally, subject to receipt of adequate funding, or with new potential collaborators.

Key Points: 
  • Sangamo is exploring avenues to resume development of these programs internally, subject to receipt of adequate funding, or with new potential collaborators.
  • In NHP studies when administered intravenously at clinically relevant doses, STAC-BBB demonstrated its potential to be a leading neurotropic capsid.
  • Exhibited 700-fold higher transgene expression in neurons compared to the benchmark capsid AAV9 and outperformed all other known published neurotropic capsid variants evaluated in the study.
  • STAC-BBB was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues.

Saint Joseph's University to Induct NEST CEO Rob Almond into Haub School of Business Hall of Fame

Retrieved on: 
Mittwoch, März 20, 2024
STAC, Saint Joseph's University, Union League of Philadelphia, Hall, Policy, Business, Education, University, Saint Joseph's, Entrepreneurship, MBA, NEST, RSVP, Management

PHILADELPHIA, March 20, 2024 /PRNewswire/ -- Saint Joseph's University announced the induction of Rob Almond, Jr., MBA '04, CEO of NEST, into the Haub School of Business Hall of Fame. As the youngest person to ever receive the honor, Almond has demonstrated exceptional leadership and innovation as Chief Executive Officer of NEST, a leading provider of Integrated Facilities Management solutions for national retailers and multi-site businesses.

Key Points: 
  • PHILADELPHIA, March 20, 2024 /PRNewswire/ -- Saint Joseph's University announced the induction of Rob Almond, Jr., MBA '04, CEO of NEST, into the Haub School of Business Hall of Fame.
  • For over 30 years, the Erivan K. Haub School of Business at Saint Joseph's University has honored corporate citizens for their excellence in business management, entrepreneurship, and ingenuity.
  • Almond exemplifies what it means to be a Hall of Famer, achieving success in business, and having a positive and tangible impact on society.
  • Rob holds an undergraduate degree from the University of North Carolina at Greensboro, where he is now a Board Member for the Bryan School of Business.

Former EUROfusion CEO, Tony Donné, to Chair General Fusion’s Science and Technology Advisory Committee

Retrieved on: 
Mittwoch, Februar 28, 2024
STAC, Neutron, Engineering, General Fusion, Magnetized target fusion, ITER, M.A, Stanford University, EUROfusion, Physics, UKAEA, LCLS, Organization, Plasma, Facility, Science, Research, European Patent Convention, SLAC National Accelerator Laboratory

RICHMOND, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Today, General Fusion announced the appointment of Tony Donné as Chair of its Science and Technology Advisory Committee (STAC).

Key Points: 
  • RICHMOND, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Today, General Fusion announced the appointment of Tony Donné as Chair of its Science and Technology Advisory Committee (STAC).
  • Prior to EUROfusion, Tony was head of the Fusion Physics Division at DIFFER and Director of the ITER-Netherlands program.
  • “General Fusion’s deeply engaged Science and Technology Advisory Committee is one of our biggest assets,” said Greg Twinney, CEO, General Fusion.
  • General Fusion Science and Technology Advisory Committee members:
    Tony Donné, Ph.D., Chair of General Fusion’s STAC and the former CEO of EUROfusion.